The FDA has approved a new drug that could help patients with a certain type of cancer. The drug, which is called pembrolizumab, is designed to treat patients with advanced non-small cell lung cancer. The approval is based on data from a clinical trial that showed the drug was effective in treating this type of cancer. The trial involved patients who had been previously treated with chemotherapy. The FDA says that the drug is safe and effective in treating this type of cancer. This is good news for patients with this type of cancer, as well as for the company that makes the drug. Sens stock is up on the news.
Pembrolizumab is a type of immunotherapy. It works by helping the body’s immune system to fight cancer cells. The drug is given as an infusion, and it is typically given every three weeks. The FDA says that the most common side effects of the drug include fatigue, nausea, diarrhea, and constipation.
Sens stock news fda approval
The FDA has approved a new drug that could help patients with a certain type of cancer. The drug, which is called pembrolizumab, is designed to treat patients with advanced non-small cell lung cancer. The approval is based on data from a clinical trial that showed the drug was effective in treating this type of cancer. The trial involved patients who had been previously treated with chemotherapy. The FDA says that the drug is safe and effective in treating this type of cancer. This is good news for patients with this type of cancer, as well as for the company that makes the drug. Sens stock is up on the news.
Pembrolizumab is a type of immunotherapy. It works by helping the body’s immune system to fight cancer cells. The drug is given as an infusion, and it typically takes about 30 minutes to receive the infusion. The FDA says that the most common side effects of the drug include fatigue, nausea, diarrhea, and constipation. The agency also says that the drug can cause serious side effects, such as low blood pressure, lung problems, and liver damage. However, these side effects are rare.
The history of Sens and how it got to where it is today
Sens was founded in the year 2000 by a group of scientists who were looking for a better way to treat cancer. The company’s first drug, pembrolizumab, was approved by the FDA in 2015. Since then, Sens has continued to develop new and innovative treatments for cancer. The company’s most recent drug, nivolumab, was approved by the FDA in 2016. Sens is a publicly traded company, and its shares are listed on the Nasdaq stock exchange.
Sens is a biopharmaceutical company that develops and commercializes immunotherapy for the treatment of cancer. The company’s lead product, pembrolizumab, is a humanized monoclonal antibody that targets the protein programmed cell death-1 (PD-1).
Why the FDA approved the drug and what it means for Sens shareholders
The FDA approved pembrolizumab for the treatment of patients with advanced non-small cell lung cancer who have been previously treated with chemotherapy. The approval is based on data from a clinical trial that showed the drug was effective in treating this type of cancer. The trial involved patients who had been previously treated with chemotherapy. The FDA says that the drug is safe and effective in treating this type of cancer. This is good news for patients with this type of cancer, as well as for the company that makes the drug. Sens stock is up on the news.
The FDA’s approval of pembrolizumab is a major milestone for Sens, and it is a significant event for the company’s shareholders. The FDA’s approval of the drug means that Sens will be able to commercialize the drug in the United States. This is a major market for the company, and it is expected to generate significant revenue for Sens.